Identifying breast cancer patients who require a double-check of preoperative core needle biopsy and postoperative surgical specimens to determine the molecular subtype of their tumor
Annals of Surgical Treatment and Research
; : 223-229, 2019.
Article
Dans En
| WPRIM
| ID: wpr-762714
Responsable en Bibliothèque :
WPRO
ABSTRACT
PURPOSE:
Core needle biopsy (CNB) is a widely used procedure for breast cancer diagnosis and analyzing results of immunohistochemistry (IHC). Several studies have shown concordance or discordance in IHC results between CNB and surgical specimens (SS). A double-check (CNB and SS) is inefficient and costly to perform a double-check on all patients. Therefore, it is important to determine which patients would benefit from a double-check.METHODS:
We collected the medical records of patients who underwent breast cancer surgery at Pusan National University Yangsan Hospital between April 2009 and June 2018 (n = 620). Molecular subtypes were classified as follows by hormone receptors (HR) and human epidermal growth factor receptor-2 (HER2) HR+/HER2+, HR+/HER2−, HR−/HER2+, HR−/HER2−. Clinicopathological factors including age, obesity, histological grade, preoperative CEA, CA15-3, T stage, N stage, and menopausal status were assessed to determine whether they were associated with subtype change.RESULTS:
Increasing histological grade (P < 0.001; odds ratio [OR], 3.693; 95% confidence interval [CI], 1.941–7.025), preoperative CEA ≥ 5 ng/mL (P =0.042; OR, 2.399; 95% CI, 1.009–5.707) and higher T stage (P = 0.015; OR, 2.241; 95% CI, 1.152–4.357) were significantly associated with subtype change. On multivariable analyses, subtype changes were more common in high-grade breast cancer (P < 0.001; OR, 1.077; 95% CI, 1.031–1.113) and CEA ≥ 5 (P = 0.032; OR, 2.658; 95% CI, 1.088–6.490).CONCLUSION:
Patients with moderate- to high-grade tumors or CEA ≥ 5 ng/mL are required a double-check to determine the molecular subtype of breast cancer.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Biopsie
/
Région mammaire
/
Tumeurs du sein
/
Immunohistochimie
/
Odds ratio
/
Dossiers médicaux
/
Diagnostic
/
Traitement médicamenteux
/
Facteur de croissance épidermique
/
Biopsie au trocart
Type d'étude:
Diagnostic_studies
/
Etiology_studies
/
Prognostic_studies
Limites du sujet:
Humans
langue:
En
Texte intégral:
Annals of Surgical Treatment and Research
Année:
2019
Type:
Article